Kinnate Biopharma Inc. Stock News

Kinnate Biopharma Inc (KNTE) shares closed today 11.5% higher than it did at the end of yesterday. The stock is currently down 53.7% year-to-date, down 51.6% over the past 12 months, and down 52.9% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $19.13 and as low as $16.02 this week.Shares closed 56.6% below its 52-week high and 15.8% above its 52-week low.Trading volume this week was 31.9% higher than the 10-day average and 88.9% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 87.4% The company's stock price performance over the past 12 months lags the peer average by 70.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Kinnate Biopharma Inc (KNTE) shares closed today 11.5% higher than it did at the end of yesterday. The stock is currently down 53.7% year-to-date, down 50.5% over the past 12 months, and down 52.9% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $19.13 and as low as $16.02 this week.Shares closed 56.6% below its 52-week high and 15.8% above its 52-week low.Trading volume this week was 37.0% higher than the 10-day average and 88.9% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 87.4% The company's stock price performance over the past 12 months lags the peer average by 68.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

AACR Special Conference: Targeting RAS presentation will highlight findings from real-world clinico-genomic study collaboration with Tempus investigating prevalence of Class II and Class III BRAF muta

JJJ Advisors Inc. acquired a new position in shares of Kinnate Biopharma Inc. (NASDAQ:KNTE) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 990 shares of the companys stock, valued at approximately $35,000. Other hedge funds and other institutional investors also []

Kinnate Biopharma Inc. (NASDAQ:KNTE)s stock price hit a new 52-week low during mid-day trading on Friday . The stock traded as low as $17.05 and last traded at $17.36, with a volume of 441 shares changing hands. The stock had previously closed at $18.14. Several brokerages have issued reports on KNTE. Jefferies Financial Group began []

Northern Trust Corp trimmed its position in Kinnate Biopharma Inc. (NASDAQ:KNTE) by 6.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 135,513 shares of the companys stock after selling 10,095 shares during the period. Northern Trust Corp owned about []

Kinnate Biopharma Inc. (NASDAQ:KNTE) Equities researchers at William Blair cut their FY2021 earnings estimates for shares of Kinnate Biopharma in a research note issued to investors on Wednesday, November 10th. William Blair analyst T. Lugo now anticipates that the company will post earnings of ($2.04) per share for the year, down from their previous []

Kinnate Biopharma Inc. (NASDAQ:KNTE) Equities research analysts at William Blair dropped their FY2021 earnings per share (EPS) estimates for shares of Kinnate Biopharma in a research report issued on Wednesday, November 10th. William Blair analyst T. Lugo now expects that the company will earn ($2.04) per share for the year, down from their prior []

The KN-8701 trial is a multi-center, open-label, two-part trial of Kinnate's lead RAF inhibitor candidate KIN-2787 The KN-8701 trial is a multi-center, open-label, two-part trial of Kinnate's lead RAF

Kinnate Biopharma (KNTE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.

SAN FRANCISCO and SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small mole

Data highlights in vitro and in vivo activity of KIN-2787 against human cancers driven by Class I, Class II and Class III BRAF mutations Data highlights in vitro and in vivo activity of KIN-2787 again

SAN FRANCISCO and SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molec